Skip to content

Sarah K. Fineberg

5 papers in the library · 29 citations · publishing 2023-2026

Papers

Sort Most recent Most cited

A protocol for MIndfulness-based Neurofeedback to augment DBT psychotherapy for adults with Borderline Personality Disorder (MIND-BPD).

PLoS One March 20, 2026 Katherine G Jones, Marlee M Vandewouw, Jitendra Awasthi et al.

Borderline personality disorder (BPD) is a severe psychiatric condition associated with high rates of suicide and poor interpersonal functioning. There are no FDA-approved medications, and evidence-based psychotherapies such as dialectical behavior therapy (DBT) are difficult to access and vulnerable to patient dropout. Novel treatment directions are urgently needed. Mindfulness is the core...

Ketamine Alters Tuning of Neural and Behavioral Spatial Working Memory Precision

bioRxiv Preprint Server February 10, 2025 Masih Rahmati, Flora Moujaes, Nina Purg Suljič et al. 1 citation preprint

Deficits in working memory (WM) are a hallmark of neuropsy-chiatric disorders such as schizophrenia, yet their neurobiological basis remains poorly understood. Glutamate N-methyl-D-aspartate receptors (NMDARs) are critical for spatial WM (sWM), with NMDAR antagonist ketamine known to attenuate task-evoked activation and reduce sWM accuracy. Cortical microcircuit models hypothesize that NMDAR...

DOI: 10.1101/2025.02.10.637233 (opens in new tab) Full text (opens in new tab) Memory deficits:memory problems Poorer memory Memory impairment Memory loss +12

Ketamine induces multiple individually distinct whole-brain functional connectivity signatures.

Elife April 17, 2024 Flora Moujaes, Jie Lisa Ji, Masih Rahmati et al. 23 citations

Ketamine has emerged as one of the most promising therapies for treatment-resistant depression. However, inter-individual variability in response to ketamine is still not well understood and it is unclear how ketamine's molecular mechanisms connect to its neural and behavioral effects. We conducted a single-blind placebo-controlled study, with participants blinded to their treatment condition....

DOI: 10.7554/elife.84173 (opens in new tab) Full text (opens in new tab) Data reduction FMRI Gene expression Human +5

A pilot randomized controlled trial of ketamine in Borderline Personality Disorder.

Neuropsychopharmacology June 2023 Sarah K. Fineberg, Esther Y Choi, Rosa Shapiro-Thompson et al.

This study is the first randomized controlled trial to test the effects of ketamine in Borderline Personality Disorder (BPD). BPD remains undertreated in the community and no medication has FDA approval for this indication. People with BPD experience chronic mood disturbances with depressed mood, suicidal ideation, and severe social difficulties. In this double-blind, randomized controlled...

Ketamine Effects on Energy Metabolism, Functional Connectivity and Working Memory in Healthy Humans

bioRxiv Preprint Server February 21, 2023 Naomi R. Driesen, Peter Herman, Margaret A. Rowland et al. 5 citations preprint

Working memory (WM) is a crucial resource for temporary memory storage and the guiding of ongoing behavior. N-methyl-D-aspartate glutamate receptors (NMDARs) are thought to support the neural underpinnings of WM. Ketamine is an NMDAR antagonist that has cognitive and behavioral effects at subanesthetic doses. To shed light on subanesthetic ketamine effects on brain function, we employed a...

DOI: 10.1101/2023.02.21.529425 (opens in new tab) Full text (opens in new tab) Ketamine pharmacology Nmdar blocker Drug effects Drug impacts +12